** Shares of therapy developer Immuneering rise 101.7% to $4.76 premarket
** Co says its therapy, IMM-1-104, showed an overall response rate of 43% in combination with gemcitabine during a mid-stage trial for patients with pancreatic cancer
** IMRX will expand the trial to include three combination treatment arms this year in addition to the existing three arms
** Co says it expects further trial data in Q2 2025
** Up to last close, stock down 64.8% in the previous 12 months
(Reporting by Christy Santhosh)
((Christy.Santhosh@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。